JOP20220092A1 - جسم مضاد لبيتا-النشواني لعلاج مرض الزهايمر - Google Patents

جسم مضاد لبيتا-النشواني لعلاج مرض الزهايمر

Info

Publication number
JOP20220092A1
JOP20220092A1 JOP/2022/0092A JOP20220092A JOP20220092A1 JO P20220092 A1 JOP20220092 A1 JO P20220092A1 JO P20220092 A JOP20220092 A JO P20220092A JO P20220092 A1 JOP20220092 A1 JO P20220092A1
Authority
JO
Jordan
Prior art keywords
beta
disease
treating alzheimer
amyloid antibody
amyloid
Prior art date
Application number
JOP/2022/0092A
Other languages
English (en)
Inventor
Edward Plowey
Haeberlein Samantha Budd
Thierry Bussiere
John Beaver
Ying Tian
Gersham Dent
Raj Rajagovindan
Roger Nitsch
Laura Nisenbaum
Original Assignee
Biogen Ma Inc
Neurimmune Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc, Neurimmune Ag filed Critical Biogen Ma Inc
Publication of JOP20220092A1 publication Critical patent/JOP20220092A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

يتعلق الاختراع الحالي بتوفير طرق لعلاج مرض الزهايمر في خاضع بشري بحاجة إليها تشتمل على إعطاء الخاضع عدة جرعات من جسم مضاد لبيتا نشواني (على سبيل المثال، أدوكانوماب).
JOP/2022/0092A 2019-10-22 2020-10-21 جسم مضاد لبيتا-النشواني لعلاج مرض الزهايمر JOP20220092A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962924633P 2019-10-22 2019-10-22
PCT/US2020/056676 WO2021081101A1 (en) 2019-10-22 2020-10-21 Anti-beta-amyloid antibody for treating alzheimer's disease

Publications (1)

Publication Number Publication Date
JOP20220092A1 true JOP20220092A1 (ar) 2023-01-30

Family

ID=73344157

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2022/0092A JOP20220092A1 (ar) 2019-10-22 2020-10-21 جسم مضاد لبيتا-النشواني لعلاج مرض الزهايمر

Country Status (13)

Country Link
US (1) US20220372123A1 (ar)
EP (1) EP4048695A1 (ar)
JP (1) JP2022553329A (ar)
KR (1) KR20220084095A (ar)
CN (1) CN114599393A (ar)
AU (1) AU2020371612A1 (ar)
BR (1) BR112022007595A2 (ar)
CA (1) CA3158513A1 (ar)
CO (1) CO2022004902A2 (ar)
IL (1) IL292363A (ar)
JO (1) JOP20220092A1 (ar)
MX (1) MX2022004678A (ar)
WO (1) WO2021081101A1 (ar)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202300517A (zh) * 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
TW202300518A (zh) * 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
IL314581A (en) * 2022-02-02 2024-09-01 Eisai R&D Man Co Ltd Treatment methods using P-TAU181 LEVEL
WO2024086796A1 (en) * 2022-10-20 2024-04-25 Alector Llc Anti-ms4a4a antibodies with amyloid-beta therapies
WO2024089620A1 (en) * 2022-10-25 2024-05-02 Institute For Basic Science (Ibs) Extracranial methods for facilitating cerebrospinal fluid drainage

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2099826E (pt) 2007-01-05 2014-01-09 Univ Zuerich Anticorpo anti-beta-amilóide e suas utilizações
MA41115A (fr) * 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
IL263433B2 (en) * 2016-06-07 2024-03-01 Biogen Int Neuroscience Gmbh Methods for treating Alzheimer's disease

Also Published As

Publication number Publication date
CO2022004902A2 (es) 2022-07-08
US20220372123A1 (en) 2022-11-24
CA3158513A1 (en) 2021-04-29
KR20220084095A (ko) 2022-06-21
JP2022553329A (ja) 2022-12-22
MX2022004678A (es) 2022-08-15
EP4048695A1 (en) 2022-08-31
AU2020371612A1 (en) 2022-05-19
CN114599393A (zh) 2022-06-07
BR112022007595A2 (pt) 2022-08-23
WO2021081101A1 (en) 2021-04-29
IL292363A (en) 2022-06-01

Similar Documents

Publication Publication Date Title
JOP20220092A1 (ar) جسم مضاد لبيتا-النشواني لعلاج مرض الزهايمر
MX2018015022A (es) Métodos para el tratamiento de la enfermedad de alzheimer.
JOP20200230A1 (ar) ناهضات ppar (مستقبل ناشر بيروكسيزوم منشط)، ومركبات، ومكونات أدوية، وطرق استعمالها
MX2021009053A (es) Anticuerpo monoclonal recombinante para usarse en el tratamiento de la enfermedad de alzheimer.
EP4389213A3 (en) Treatment of fabry disease in ert-naive and ert-experienced patients
EA201892190A1 (ru) Лечение псориаза антителом к ил-12 и/или ил-23 с возрастанием интервала между введениями дозы
MY184890A (en) Improved a? protofibril binding antibodies
MX2021002321A (es) Nuevos metodos.
MX2018012538A (es) Agonistas del receptor activado por proliferador de peroxisoma (ppar), compuestos, composiciones farmaceuticas y metodos para usar los mismos.
MY187358A (en) Modified release orally administered amino acid formulations
MX2021007235A (es) Tubulisinas y conjugados de proteina-tubulisina.
MX2018010032A (es) Formulaciones de antagonista de il-6 y sus usos.
CR20220216A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
AR119159A1 (es) Tratamientos de angioedema
MX2022015769A (es) Tubulisinas y conjugados de proteina-tubulisina.
EP4282485A3 (en) Dosage regimen for pegylated interferon
MX2018005226A (es) Formulaciones de anticuerpo anti-factor d.
WO2023081194A3 (en) Methods for treating alzheimer's disease
MX2021009326A (es) Pridopidina de dosis baja para mal de parkinson y otras enfermedades asociadas con parkinsonismo.
MX2021012967A (es) Anticuerpos y formulaciones de anti-cd38.
MX2020013684A (es) Formulaciones/composiciones que comprenden ibrutinib.
WO2020092533A3 (en) Methods of treatment using anti-cd123 immunoconjugates
PH12020550024A1 (en) Pharmaceutical combinations comprising an anti bst-1 antibody and a cytidine analogue
AU2017260751A1 (en) Tablet-in-tablet pharmaceutical composition comprising cyclophosphamide and capecitabine
EA201892739A1 (ru) Способы лечения болезни альцгеймера